Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 96 for your search:
Cancer Type/Condition:
Ovarian epithelial cancer
Stage/Subtype:
stage IV ovarian epithelial cancer
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
Other
Protocol IDs:
20050113
, NCT00243685
2.
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
WIRB 20060042
, NCT00443196
3.
Phase III Randomized Study of Paclitaxel Versus Polyglutamate Paclitaxel as Consolidation/Maintenance Therapy Versus No Further Anticancer Therapy Until Disease Progression in Patients With Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer or Fallopian Tube Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
GOG-0212
, NCT00108745
4.
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
KTN32313R
, NCT00477282
5.
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
110655
, AGO-OVAR16, NCT00866697
6.
Phase III Randomized Study of Bevacizumab in Combination With Intravenous Versus Intraperitoneal Chemotherapy in Patients With Stage II, III, or IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Carcinoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
GOG-0252
, GOG -0252, NCT00951496
7.
BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
1199.15
, EudraCT: 2008-006831-10, AGO-OVAR12, NCT01015118
8.
Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell Chimerism After Nonmyeloablative Allogeneic Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
FHCRC-1825.00
, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
9.
Phase I/II Study of Ixabepilone and Pegylated Doxorubicin HCl Lipsome in Women With Previously Treated Advanced Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer or Metastatic Breast Cancer (Phase I Closed to Accrual as of 12/6/07)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
AECM-0504007857
, NCI-7229, 7229, NCT00182767
10.
Phase I/II Randomized Study of Docetaxel With Versus Without Phenoxodiol in Patients With Recurrent Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
YALE-HIC-27640
, YALE-012705, NCT00303888
11.
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GYN06-111
, NCT00526799
12.
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
A/100/0501
, NCT00660101
13.
AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
20070411
, NCT00819169
14.
Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer With Symptomatic Ascites
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
BC-08-01
, NCT00826150
15.
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CR015580
, NCT00841191
16.
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ITL-002-CRYO
, NCT00861107
17.
Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CDX1401-01
, NCT00948961
18.
Phase II Study of Whole Body Hyperthermia Combined With Doxorubicin HCl Liposome and Fluorouracil in Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UTHSC-MS-96205
, NCI-V97-1356, NCT00003135
19.
Phase II Study of Cisplatin and Flavopiridol in Patients With Advanced Ovarian Epithelial or Primary Peritoneal Cancer (Group 2 closed to accrual as of 3/10/06)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0261
, 5876, NCI-5876, NCT00083122
20.
Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
Å6-003
, NCT00083928
21.
Phase II Study of Gemcitabine Hydrochloride and 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Recurrent Advanced Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0362
, 6307, NCI-6307, NCT00093496
22.
Phase II Study of Denileukin Diftitox in Patients With Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UTHSC-HSC20070042H
, HSC20070042H, TULCC-TC-01-4, TULCC-C0307, NCT00238186
23.
Allogeneic Transplantation From Related Haploidentical Donors in Older Patients With Indolent Hematologic Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Older patients
Sponsor:
NCI, Other
Protocol IDs:
BMT124
, 75117, BMT124, NCT00185692, NCT00185692
24.
DOXIL for Consolidation Therapy in Ovarian Cancer.
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
SEGO_DOXIL_CONS2005
, NCT00248248
25.
Phase II Randomized Study of Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UMN-2005NT018
, UMN-0506M70866, UMN-MT2005-06, NOVARTIS-CZOL446EUS29, NCT00321932
Select All on Page
1
Help with Results
